Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
See Latest ArticlesFesoterodine for the treatment of urinary incontinence and overactive bladder
Therapeutics and Clinical Risk Management, 11/04/09
Ellsworth P – Fesoterodine is one of the newest antimuscarinic agent approved for the management of OAB. It is unique in that it shares the same active metabolite as tolterodine, 5–hydoxymethyltolterodine (5–HMT); however, this conversion is established via ubiquitous esterases and not via the cytochrome P450 system, thus providing a faster and more efficient conversion to 5–HMT. Fesoterodine is available in 2 doses, 4 mg and 8 mg. Clinical trials have established a dose response relationship in efficacy parameters as well as improvements in quality of life. As with all antimuscarinics, dry mouth and constipation are the more common side effects. A combination of medical therapy and behavioral therapy improves the overall outcome in management of OAB. Dose flexibility may help improve efficacy outcomes and patient education on the management of common adverse effects may improve tolerability with these agents.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Sponsor
Article Search
Sponsor
Sponsor